LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key... LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system functions.
- Mechanism
- Curator reviewed
LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system functions.
- Primary indication
- Irritable bowel syndrome (IBS) and other gastrointestinal disordersCurator reviewed
- Code names
- LX1031
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with LX1031, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account